Clinical trial NCT05189938: HbA1c Variation Study
Official title: HbA1c Variation Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus
Keywords: Professional FreeStyle Libre Flash Glucose Monitoring System
HBA1C
Lead sponsor: Abbott Diabetes Care
Sponsor class: INDUSTRY
First posted: 2022-01-13
Enrollment: 488
Sex: ALL
Minimum age (years): 4
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with type 1 or 2 diabetes.

Brief summary: To evaluate the relationship between glycated hemoglobin (HbA1c) and average glucose levels using continuous glucose monitoring.

Detailed description: This is a non-pivotal , non-randomized, single-arm, multi-center, prospective, non-significant risk study to evaluate the relationship between glycated hemoglobin (HbA1c) and average glucose levels. Up to approximately 600 subjects will be enrolled who will have fourteen (14) study visits over the course of approximately six (6) months. During each visit the subject will have blood samples drawn for documentation of their HbA1c level. Subjects will also be required to wear Professional FreeStyle Libre Flash Glucose Monitoring System(s) to record blood glucose levels through the duration of the study. During Visits 1 and 14, Venous sample for CBC, biochemistry, haemoglobinopathy screen, hematology, liver function and iron panels will be collected.

Eligibility criteria: Inclusion Criteria:

1. Subject must have type 1 or type 2 diabetes.
2. Subject is at least 4 years old.
3. Point-of-care (POC) HbA1C of 3.0%-15.5% (9 mmol/mol - 146 mmol/mol)
4. Subject must be able to read and understand English.
5. In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
6. Subject must be available to participate in all study visits.
7. Subject must be willing and able to provide written signed and dated informed consent.
8. Subjects age 4 - 17: Parent or guardian must be willing and able to provide written signed and dated informed consent.
9. Subjects age 11 - 17 Subject must be willing and able to provide written signed and dated informed assent.

   Exclusion Criteria:
10. Subject is currently undergoing dialysis or planning to receive dialysis during the course of the study
11. History of blood transfusion in the last 3 months or planned blood transfusion during the course of the study.
12. Subject is currently planning to undergo a major medical intervention expected to significantly alter red cell life span, i.e. chemotherapy, major surgery requiring blood transfusions, etc.
13. Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
14. Subjects age 18 and older: Subject is known to be pregnant, attempting to conceive or is not willing and able to practice birth control during the study duration study (applicable to female subjects only). Subjects age 17 and younger: Subject is known to be pregnant at the time of study enrollment or is planning to become pregnant during the study (applicable to female subjects only).
15. Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
16. Subject has a pacemaker or any other neurostimulators.
17. Subject has concomitant medical condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the subject or study staff.
18. Subject is currently participating in another interventional clinical trial.
19. Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Primary outcomes:
measure: Establish a relationship between laboratory-derived HbA1c and average glucose levels
timeFrame: six (6) months
Secondary outcomes:
Other outcomes:
Locations:
city: Miami Gardens
country: United States
facility: Excellence Research and Medical
state: Florida
city: Idaho Falls
country: United States
facility: Rocky Mountain Clinical Research
state: Idaho
city: Billings
country: United States
facility: Billings Clinic
state: Montana
city: Albuquerque
country: United States
facility: Albuquerque Neuroscience Inc.
state: New Mexico
city: Anderson
country: United States
facility: Anmed Health Internal Medicine Associates
state: South Carolina
city: Flower Mound
country: United States
facility: Prime Revival Research Institute
state: Texas
city: Redmond
country: United States
facility: Eastside Research Associates
state: Washington
city: Renton
country: United States
facility: Rainier Clinical Research Center
state: Washington
city: Birmingham
country: United Kingdom
facility: University Hospital Birmingham
city: Bradford
country: United Kingdom
facility: Bradford Royal Infirmary
city: Derby
country: United Kingdom
facility: Royal Derby Hospital
city: Edinburgh
country: United Kingdom
facility: Edinburgh Royal Infirmary
city: Harrow
country: United Kingdom
facility: Northwick Park Hospital
city: Hull
country: United Kingdom
facility: Hull Royal Infirmary
city: Leeds
country: United Kingdom
facility: St James University Hospital
city: Leicester
country: United Kingdom
facility: Leicester General Hospital
city: Manchester
country: United Kingdom
facility: Manchester Royal Infirmary
city: Nottingham
country: United Kingdom
facility: Nottingham Children's Hospital & Queen's Medical Centre
city: Reading
country: United Kingdom
facility: Royal Berkshire Hospital
city: Sheffield
country: United Kingdom
facility: Northern General Hospital
city: Southall
country: United Kingdom
facility: Ealing Hospital
city: Whitechapel
country: United Kingdom
facility: The Royal London Hospital
Study officials:
affiliation: Abbott Diabetes Care
name: Shridhara A Karinka, PhD
role: STUDY_DIRECTOR
References: